CALA — Calithera Biosciences Cashflow Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.02m
- -$25.43m
Annual cashflow statement for Calithera Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -54.6 | -89.9 | -90.1 | -115 | -39.6 |
Depreciation | |||||
Non-Cash Items | 7.17 | 6.93 | 9.42 | 51.9 | 3.21 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -17.9 | 3.7 | -3.96 | -3.4 | -7.43 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -64.8 | -78.7 | -84.3 | -66.3 | -43.6 |
Capital Expenditures | -0.214 | -0.007 | -0.061 | -0.147 | -0.133 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 53 | -10.8 | 89 | 8 | 0 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 52.8 | -10.8 | 89 | 7.85 | -0.133 |
Financing Cash Flow Items | — | — | — | -0.173 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 14.6 | 98.9 | 42.1 | 10.7 | 9.65 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 2.58 | 9.38 | 46.7 | -47.8 | -34.1 |